biosimilars_for_psoriasis_worldwide_overview_of_regulatory_guidelines,_uptake_and_implications_for_dermatology_clinical_practice.br_j_dermat_资料4.Image.Marked.pdf

PROFESSOR ARNON D. COHEN (Orcid ID : 0000-0002-8377-9982) DR JOELLE VAN DER WALT (Orcid ID : 0000-0002-4916-487X) e DR ANDREW BLAUVELT (Orcid ID : 0000-0002-2633-985X) l c Article type : Review Article i t Category: Review article Biosimilars for Psoriasis: Worldwide Overview of Regulatory Guidelines, Uptake and Implications for r Dermatology Clinical Practice A Running Head: Uptake of Biosimilars for Psoriasis 1 2 3 4 5 6 7 A.D. Cohen , J.J. Wu, L. Puig , S. Chimenti , R. Vender , M. Rajagopalan , R. Romiti , C. de la 8 9 9 10 11 12 13 d Cruz ; L. Skov , C. Zachariae , H.S. Young , P. Foley , J.M. van der Walt , L. Naldi and A. e Blauvelt14 t 1Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben- Gurion University of the Negev, Beer-Sheva and Department of Quality Measurements and Research, p Chief Physician’s Office, Clalit Health Services, Tel Aviv, Israel 2Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, e U.S.A. c 3Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain c 4University of Rome Tor Vergate, Rome, Italy This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may